Full history for every metric is available with a Kvantra account
Theseus Pharmaceuticals, Inc. (THRX)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -54 | -67 | |||||
| Net profit | $m | - | - | -7 | -12 | -27 | -47 | -56 |
| EPS reported | $ | -1.22 | -1.34 | |||||
| Operating cashflow per share | $ | -0.86 | -0.86 | |||||
| Capex per share | $ | 0.01 | 0.01 | |||||
| FCF per share | $ | -0.87 | -0.87 | |||||
| Free cash flow | $m | -33 | -50 | |||||
| Net debt | $m | -194 | -205 | |||||
| Book value equity | $m | 208 | 225 | |||||
| Book value per share | $ | 5.39 | 5.13 | |||||
| Number of shares | m | 38.49 | 43.8 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.92 | 0.81 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -5.74 | -3.65 | |||||
| EV/EBITDA LTM | x | -1.87 | 0.38 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -24.56% | -30.09% | |||||
| FCF Yield | % | -17.42% | -27.38% | |||||
| Quality | ||||||||
| ROE | % | -22.68% | -20.74% | |||||
| ROIC | % | -23.73% | -23.73% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -8.39 | -13.59 | |||||
| Net Debt/EBITDA | x | 1.68 | 1.68 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -101.21% | -113.02% | |||||
| Net debt/Equity | x | -0.93 | -0.91 | |||||
| Gross debt/equity | x | 0.02 | 0.02 | |||||
Company overview
Theseus Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and bringing to market targeted treatments for cancer patients. Their leading investigational compound, THE-630, is a pan-KIT inhibitor undergoing Phase I clinical trials for treating gastrointestinal stromal tumors. The company is also advancing a fourth-generation EGFR inhibitor specifically designed to combat the C797S EGFR mutation, which confers resistance to initial or later-line osimertinib therapy in individuals with non-small cell lung cancer. All their research and development efforts aim to overcome drug resistance mutations within key driver oncogenes, which are mutated genes that promote cancer. Founded in 2017, the company operates out of Cambridge, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Theseus Pharmaceuticals, Inc. (THRX)
Theseus Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and bringing to market targeted treatments for cancer patients. Their leading investigational compound, THE-630, is a pan-KIT inhibitor undergoing Phase I clinical trials for treating gastrointestinal stromal tumors. The company is also advancing a fourth-generation EGFR inhibitor specifically designed to combat the C797S EGFR mutation, which confers resistance to initial or later-line osimertinib therapy in individuals with non-small cell lung cancer. All their research and development efforts aim to overcome drug resistance mutations within key driver oncogenes, which are mutated genes that promote cancer. Founded in 2017, the company operates out of Cambridge, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free